key: cord-0985006-4h8a96gv
authors: Zhang, Anna Jinxia; Lee, Andrew Chak-Yiu; Chan, Jasper Fuk-Woo; Liu, Feifei; Li, Can; Chen, Yanxia; Chu, Hin; Lau, Siu-Ying; Wang, Pui; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Yuan, Shuofeng; To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung
title: Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters
date: 2020-11-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1747
sha: 343f821a978bf4b64c451c86d077adca66c4a23b
doc_id: 985006
cord_uid: 4h8a96gv

BACKGROUND: Clinical outcomes of the interaction between the co-circulating pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and seasonal influenza viruses are unknown. METHODS: We established a golden Syrian hamster model co-infected by SARS-CoV-2 and mouse-adapted A(H1N1)pdm09 simultaneously or sequentially. The weight loss, clinical scores, histopathological changes, viral load and titer, and serum neutralizing antibody titre were compared with hamsters challenged by either virus. RESULTS: Co-infected hamsters had more weight loss, more severe lung inflammatory damage and tissue cytokine/chemokine expression. Lung viral load, infectious virus titers and virus antigen expression suggested that hamsters were generally more susceptible to SARS-CoV-2 than A(H1N1)pdm09. Sequential co-infection with A(H1N1)pdm09 one day prior to SARS-CoV-2 exposure resulted in a lower lung SARS-CoV-2 titer and viral load than with SARS-CoV-2 infection alone, but a higher lung A(H1N1)pdm09 viral load. Co-infection also increased intestinal inflammation with more SARS-CoV-2 nucleoprotein expression in enterocytes. Simultaneous co-infection was associated with delay in resolution of lung damages, lower serum SARS-CoV-2 neutralizing antibody and longer SARS-CoV-2 shedding in oral swabs compared to that of SARS-CoV-2 infection alone. CONCLUSIONS: Simultaneous or sequential co-infection by SARS-CoV-2 and A(H1N1)pdm09 caused more severe disease than infection by either virus in hamsters. Prior A(H1N1)pdm09 infection lowered SARS-CoV-2 pulmonary viral loads but enhanced lung damage. Whole-population influenza vaccination for prevention of co-infection, and multiplex molecular diagnostics for both viruses to achieve early initiation of antiviral treatment for improvement of clinical outcome should be considered.

The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 50 million people with over 1.2 million deaths in the last 10 months [1]. SARS-CoV-2 emerged in December of 2019 as a cluster of cases of pneumonia related to a food market in the city of Wuhan in China. High person-to-person transmissibility was demonstrated in intrafamilial settings [2] , and other indoor settings with suboptimal ventilation where people gathered together without mask protection such as in eateries, bars, cruise ships, fitness clubs, conference halls, pantries of workplace, religious premises and elderly homes [3] [4] [5] . Though over 60% of patients developed symptoms at some stage in time, 4.2% to 44% of the transmissions can occur during the pre-symptomatic stage of infection [6] . Moreover the SARS-CoV-2 viral load often peaks around symptom onset or at presentation of COVID-19 instead of around day 10 after symptom onset as in the case of 2003 SARS which hampers the efficacy of isolation and contact tracing [7, 8] . Clinical manifestations of COVID-19 vary from mild upper respiratory symptoms to progressive lower respiratory involvement which can terminate in respiratory failure and multi-organ involvement. The COVID-19 syndrome is not clinically or pathologically distinct from influenza. While seasonal influenza has a crude case fatality rate of 0.1% to 0.2%, the estimated crude mortality rate of COVID-19 is around 1 to 2% [9, 10] . Both cause severe disease in the elderly, comorbid and obese patients [11] . As the winter influenza season of 2020 is approaching, we are anticipating an increasing number of co-infections with COVID-19. In a meta-analysis, 3% of hospitalized COVID-19 patients had co-infections with other respiratory viruses of which respiratory syncytial virus and influenza A virus were the most common [12] . Analysis of cases of influenza and COVID-19 coinfections in the UK National surveillance showed that the co-infected patients had a 5.9 times greater risk of death [13] . Moreover, mathematical modelling suggested that the A c c e p t e d M a n u s c r i p t 6 decrease of COVID-19 cases in the spring of 2020 was not only related to epidemiological control measures but also to the ending of the influenza season, and that influenza may have increased transmission of SARS-CoV-2 by 2 to 2.5 folds [14] . Furthermore, co-infection of guinea pigs by the 2003 SARS-CoV and a human reovirus isolated from a SARS patient has resulted in more rapid animal death from diffuse alveolar damage [15] . Previously, we set up the golden Syrian hamster model of COVID-19 by intranasal inoculation with SARS-CoV-2 which reproduces the clinical signs, pathological changes, serological response and transmissibility of this viral pneumonia [16, 17] . Coincidentally, hamsters were found susceptible to infection by the 2009 pandemic H1N1 virus [A(H1N1)pdm09] and other seasonal influenza viruses with weight loss, infectious virus shedding, and viral antigen expression in the respiratory tract [18] . In this study, we titrate for the lower dose of virus inoculum of A(H1N1)pdm09 or SARS-CoV-2 that can cause significant histopathological changes of viral pneumonia in the hamsters. The clinical scores, weight loss, histopathological changes, immunohistochemical antigen expression pattern, degree of individual virus replication, and serological responses in hamsters co-infected by both viruses either simultaneously or sequentially are described and analyzed.

SARS-CoV-2 HKU-13 strain (GenBank accession number: MT835140) was isolated from a COVID-19 patient [19] . The influenza virus was a mouse adapted strain of A(H1N1)pdm09 named A/HK/415742/2009 [20] . The virus stocks were prepared and titrated for plaque 

The virus stock was diluted in phosphate-buffered saline (PBS) to a total volume of 50μl inoculum was intranasally inoculated into the hamster under ketamine (200mg/kg) and xylazine (10mg/kg) anesthesia [16] . Mock-infected animals were given the same volume of PBS. For single virus infection experiments, inocula of 10 2 , 10 4 or 10 6 PFUs A(H1N1)pdm09 were used; whereas 10 or 10 3 PFUs of SARS-CoV-2 was used. In the co-infection study, 10 3 PFUs of SARS-CoV-2 and 10 5 PFUs of A(H1N1)pdm09 were used for high inoculum group; while 10 PFUs of SARS-CoV-2 and 10 4 PFUs of A(H1N1)pdm09 were used for low inoculum group. For simultaneous co-infection, the two viruses were mixed together into a 50ul of inoculum for each animal. For sequential low inoculum co-infection, the second virus inoculum was given 24 hours after the first virus challenge ( Figure 1A 

Lung and nasal turbinate tissues were homogenized and viral load was determined by RT-qPCR as we described previously [21, 22] . Infectious viral titer was determined by plaque assay in Vero E6 and MDCK cells respectively [23, 24] .

Formalin-fixed and paraffin-embedded lung, nasal turbinate, and small intestine tissues were cut into 4µm tissue sections and stained with hematoxylin and eosin (H&E) for histopathological examination. To differentiate the severity of lung tissue damage, each category of the histopathology changes for alveolitis including pulmonary edema, alveolar infiltration and blood vessel inflammation were assessed and scored 0-4 as we described previously (Supplementary table 1) [25, 26] . Viral antigens were stained by immunohistochemistry or immunofluorescences with specific antibodies: rabbit anti-SARS-CoV-2 nucleocapsid (N) antibody or mouse anti-influenza A nucleoprotein (NP) antibody [27] [28] [29] .

Total RNA extracted from lung and nasal turbinate tissues was reverse transcribed into cDNA with MiniBEST Universal RNA Extraction Kit (Takara) and PrimeScriptTM RT reagent kit (Takara). RT-qPCR was performed with gene specific primers (Supplementary 

Neutralizing antibody titer against SARS-CoV-2 and A(H1N1)pdm09 in serum taken at 7dpi and 14dpi were determined by microneutralization assay in Vero E6 and MDCK cells as we previously described [26, 30] .

All data were analyzed with Prism 8.0 (GraphPad Software Inc). Student's t-test and one-way ANOVA were used to determine significant differences among different groups. P<0.05 was considered statistically significant.

To find the optimal virus inoculum to induce pneumonia, we challenged hamsters by intranasal inoculation with 10 2 , 10 4 or 10 6 PFUs of mouse adapted A(H1N1)pdm09. Only animals receiving 10 6 PFUs inoculum lost 6.3% body weight at 2dpi ( Figure 1B ). Though their lung viral load at 4dpi correlated with the dose of inocula ( Figure 1C ), there were no significant differences. Higher inoculum with 10 4 or 10 6 PFUs upregulated innate immune gene expression in the lungs which included interferon (IFN)-α, IFN-γ, IL-1β, IL-6, TNF-α MIP-1α, RANTES and IP-10 ( Figure 1D ). Histologically, the lung tissue showed localized peribronchiolar and perivascular infiltration. The size and severity of affected lung area correlated with the dose of virus inoculum. But even the highest inoculum of 10 6 PFUs did not cause conspicuous alveolar space infiltration or exudation ( Figure 1E ). Immunohistochemical staining for influenza virus nucleoprotein demonstrated extensive antigen expression in the nasal turbinate, trachea, bronchi and bronchioles which were, but much less frequently, found in the pulmonary alveolar epithelium ( Figure 1E ). M a n u s c r i p t 

To understand the impact of co-infection, we challenged hamsters intranasally with an inoculum of SARS-CoV-2 (10 3 PFUs) and A(H1N1)pdm09 (10 5 PFUs) mixed together, with SARS-CoV-2 (10 3 PFUs) alone, or with A(H1N1)pdm09 (10 5 PFUs) alone respectively as controls. Co-infected hamsters showed a maximum weight loss of 12.5% at 4dpi (versus 8.4% in SARS-CoV-2 alone and 7% in A(H1N1)pdm09 infections alone), but the differences were not significant ( Figure 2A ). Co-infected animals showed signs of disease at 3dpi with a significantly higher clinical score at 4dpi ( Figure 2B ). Except for the lung infectious virus titer of SARS-CoV-2 which was significantly higher in single SARS-CoV-2 infection than co-infection, no significant difference in viral load or infectious virus titer for either A(H1N1)pdm09 or SARS-CoV-2 was found in other groups ( Figure 2C and 2D). Similar degree of severe pulmonary alveolitis was observed in high dose co-infected or 10 3 PFUs SARS-CoV-2 singly infected animals ( Figure 2E ).

To allow better differentiation of the effects of virus co-infection, the inoculum dose was reduced to SARS-CoV-2 (10PFUs) and A(H1N1)pdm09 (10 4 PFUs) given by simultaneous or sequential challenge and compared with controls of single virus infection using the same dose of inoculum ( Figure 1A ). While animal challenge by A(H1N1)pdm09 alone did not cause weight loss, SARS-CoV-2 challenge alone caused 5.8%, and the co-infection caused 9.6% of weight loss at 4dpi ( Figure 3A ) with no significant differences in clinical scores among different groups ( Figure 3B ). Histopathological examination of co-infected animals at 4dpi showed extensive and conspicuous pulmonary alveolar exudation ( Figure 3C ). The histology A c c e p t e d M a n u s c r i p t 11 score in terms of pulmonary edema, inflammatory cell infiltration and vasculitis were higher in co-infected animals than the single virus infected animals ( Figure 3D ). Sequential inoculation of SARS-CoV-2 and A(H1N1)pdm09 24 hours apart also caused severe pulmonary alveolitis ( Figure 3H left and middle), which were comparable to 10 3 PFU (high dose) SARS-CoV-2 infection ( Figure 3H , right).

Though there was a time difference of 24 hours in the duration of challenge by the second virus in sequential co-infection when compared with simultaneous co-infection ( Figure 1A As for extrapulmonary pathology, increased intestinal inflammatory infiltration and edema were observed in co-infected animals at 4dpi ( Figure 5A ). In the intestinal sections, SARS-CoV-2 N antigen expressing enterocytes were more easily seen in co-infected hamster than in SARS-CoV-2 single infection by immunofluorescence ( Figure 5B ). However, no A(H1N1)pdm09 NP antigen were detected from intestinal sections. Serum neutralizing antibody titer against A(H1N1)pdm09 was slightly lower in co-infected animals than single A(H1N1)pdm09 infection at 7 and 14dpi, but not significantly different ( Figure 6C ). The clinical score, maximal weight loss, histology score, virologic profile, antigen expression and neutralizing antibody titers in different groups of infected or coinfected hamsters were summarized in Table 1 .

In this study, we confirmed that hamsters are susceptible to mouse adapted A(H1N1)pdm09 [18] and human isolate of SARS-CoV-2 [16] . Moreover, hamsters appeared to be more susceptible to SARS-CoV-2 with a lower inoculum dose but had more weight loss (Table 1) The clinical significance of acute respiratory virus co-infections in terms of hospital stay, the need for intensive care, and mortality rate is controversial [31] . While data for adults are lacking, most studies suggested that the clinical severity is not different between children with single respiratory virus infection and virus coinfection but the mortality is higher in preschool children [32] . The historically unprecedented co-circulation of SARS-CoV-2 and seasonal influenza poses a great challenge to our healthcare system in the 2020 winter. An epidemiological study showed that the risk of testing positive for SARS-CoV-2 was 68% lower among influenza positive cases which suggested possible interference or competition between these two viruses [13] , while co-infection with both viruses had greater risk of A c c e p t e d M a n u s c r i p t 15 ventilator use, intensive care admission and death [33] . Since the control for the type of respiratory viruses, their relative dose, order of acquisition, route to the upper or lower airway, and the effect of viral interference in different age or comorbid patient groups are not clinically possible, we set up this hamster co-infection model to understand the significance of this potentially ominous interaction between a new emerging pandemic coronavirus and the presently circulating seasonal influenza A(H1N1)pdm09. Our findings are consistent with the epidemiological study in that the animal lung pathology was more severe with simultaneous or sequential co-infections. This finding is consistent with the previous report of more severe lung pathology in guinea pigs co-infected by 2003 SARS-CoV and reovirus isolated from a SARS patient [15] . Interestingly, infectious SARS-CoV-2 titer was also increased in nasal turbinate of hamsters with preceding A(H1N1)pdm09 inoculation which is compatible with an epidemiological modelling study suggesting that SARS-CoV-2 transmission increased 2-2.5 folds due to co-infection with influenza [14] . Finally, the SARS-CoV-2 viral load were lower in the lungs of hamsters with preceding A(H1N1)pdm09 inoculation which suggested A(H1N1)pdm09 outcompeted SARS-CoV-2 in this setting.

Our previous study showed that resolution of inflammatory lung damages due to SARS-CoV-2 should be complete after 7dpi [16] . The present study showed that the inflammatory damages due to A(H1N1)pdm09 was mild. Besides the severity of lung damage by coinfection and higher inflammatory cytokine/chemokine responses, we observed a delay of resolution of lung inflammation in co-infected hamsters even by 14dpi. This was accompanied by a significantly lower neutralizing antibody titer against SARS-CoV-2 but not for A(H1N1)pdm09. Based on these findings of increased disease severity, delayed resolution and lung healing, and a blunted adaptive immune response, a high compliance to population wide vaccination against seasonal influenza is warranted to prevent severe diseases resulting A c c e p t e d M a n u s c r i p t 16 from co-infection with SARS-CoV-2 since an effective antiviral against SARS-CoV-2 is still lacking or not readily available. Early detection of co-infection by multiplex RT-PCR could be important for early initiation of antivirals within 48 hours of symptom onset to improve the prognosis of patients with co-infection.

Viral interference is a phenomenon where one virus competitively suppresses the replication of another co-infecting virus, and is generally believed to down-modulate virus virulence, cell death, disease severity and transmissibility [34] . In terms of acute respiratory virus coinfection animal model, a mouse model of co-infection by influenza A PR8 virus and rhinovirus or mouse hepatitis virus was reported to show an attenuation of disease severity when rhinovirus or mouse hepatitis virus was given 2 days prior to the influenza virus [35] .

Similarly, another ferret study showed reduction of the severity of influenza if prior respiratory syncytial virus was given [36] . In our study, though A(H1N1)pdm09 appeared to interfere with SARS-Co-2 replication, it actually increased the disease severity. Viral A c c e p t e d M a n u s c r i p t 17 Besides hamsters, human ACE2 transgenic mice, ferrets and primates are possible options for developing laboratory animal models of co-infection as they are all susceptible to SARS-CoV-2 and influenza virus [37] . In terms of cost, availability, ease of manipulation and simulation to human disease, the hamster model was chosen for this study. Our study has limitations due to the differences in the intrinsic susceptibility of hamsters to SARS-CoV-2 and A(H1N1)pdm09. While the laboratory hamsters are immunologically naïve to both viruses, patients generally have some degree of immunity against seasonal influenza viruses.

Our study has only used A(H1N1)pdm09 but not influenza A (H3N2) The images of SARS-CoV-2 single infection shows N protein expression in regional alveoli and bronchiolar epithelium (arrows); simultaneously co-infected lung has small patches of N protein expression in a large area of inflammatory consolidated lung tissue (arrows); the lung co-infected sequentially by SARS-CoV-2 prior to pH1N1 (SARS-CoV-2 || pH1N1) shows extensive N protein expression distributed diffusely in the lung; while in sequential co-infection by pH1N1 prior to SARS-CoV-2 (pH1N1 || SARS-CoV-2), the large area of inflammatory consolidation in lung tissue shows a few N protein positive cells.

(D) Immunofluorescence images illustrate pH1N1 NP antigen and SARS-CoV-2 N antigen in single virus infected hamster lung tissues. pH1N1 NP is only seen in the epithelium of bronchiolar epithelium, not in alveoli (NP, green). SARS-CoV-2 N antigen is seen diffusely distributed in alveoli (N, red) (E) Dual immunofluorescence images illustrate the distribution of pH1N1 NP and SARS-CoV-2 N in simultaneously co-infected hamster nasal turbinate (upper panels) and lung tissues (lower panels). pH1N1 NP antigen was rarely seen in the co-infected nasal turbinate tissues while SARS-CoV-2 N protein was abundantly detected (arrows, N stained red). In the lung tissue, the two viral antigens also distributed differently. These 

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series

The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2

The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?

Is presymptomatic spread a major contributor to COVID-19 transmission

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. The Lancet Microbe

World Health Organization. Coronavirus disease (COVID-19): Similarities and differences with influenza

Two years after pandemic influenza A/2009/H1N1: what have we learned?

Co-infections in people with COVID-19: a systematic review and meta-analysis

Interactions between SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative design

Influenza may facilitate the spread of SARS-CoV-2

Pathology of guinea pigs experimentally infected with a novel reovirus and coronavirus isolated from SARS patients

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for Coronavirus Disease 2019 (COVID-19)

Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection

SARS-CoV-2 spike D614G variant exhibits highly efficient replication and transmission in hamsters

D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Avian influenza virus A H7N9 infects multiple mononuclear cell types in peripheral blood and induces dysregulated cytokine responses and apoptosis in infected monocytes

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe

Prostaglandin E2-mediated impairment of innate immune response to A(H1N1)pdm09 infection in diet-induced obese mice could be restored by paracetamol

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters

Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters

Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters

Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19

Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with dietinduced obesity

Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes

Respiratory Virus Co-infection in Acute Respiratory Infections in Children

Clinical disease severity of respiratory viral co-infection versus single viral infection: a systematic review and metaanalysis

The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak

Virological and Immunological Outcomes of Coinfections

Attenuation of Influenza A Virus Disease Severity by Viral Coinfection in a Mouse Model

Investigating Viral Interference Between Influenza A Virus and Human Respiratory Syncytial Virus in a Ferret Model of Infection

Animal models for COVID-19

Acknowledgements and financial support. This study was partly supported by funding from

A c c e p t e d M a n u s c r i p t 19 A c c e p t e d M a n u s c r i p t